Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study

PURPOSE: Entecavir demonstrated superior virologic and biochemical benefits over lamivudine at 48 weeks in nucleoside-naïve Chinese patients with chronic hepatitis B (CHB). We evaluated the effect of continued entecavir and lamivudine treatment in patients who continued treatment in year 2 and the o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Guangbi, Chen, ChengWei, Lu, WeiLun, Ren, Hong, Tan, DeMing, Wang, YuMing, Xu, DaoZheng, Liu, Jessica, Xu, Dong, Llamoso, Cyril
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716907/
https://www.ncbi.nlm.nih.gov/pubmed/19669324
http://dx.doi.org/10.1007/s12072-008-9088-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716907/
https://www.ncbi.nlm.nih.gov/pubmed/19669324
http://dx.doi.org/10.1007/s12072-008-9088-8

Ejemplares similares